NASDAQ: FBIO
Fortress Biotech Inc Stock Forecast, Predictions & Price Target

Analyst price target for FBIO

Based on 2 analysts offering 12 month price targets for Fortress Biotech Inc

Min Forecast
$16.00+803.95%
Avg Forecast
$21.00+1,086.44%
Max Forecast
$26.00+1,368.93%

Should I buy or sell FBIO stock?

Based on 2 analysts offering ratings for Fortress Biotech Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although FBIO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates FBIO as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their FBIO stock forecasts and price targets.

FBIO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-11
lockedlocked$00.00+00.00%2024-11-18

1 of 1

Forecast return on equity

Is FBIO forecast to generate an efficient return?

Company
N/A
Industry
142.9%
Market
80.27%

Forecast return on assets

Is FBIO forecast to generate an efficient return on assets?

Company
N/A
Industry
35.65%

FBIO earnings per share forecast

What is FBIO's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$1.51
Avg 2 year Forecast
-$1.01
Avg 3 year Forecast
-$0.46

FBIO revenue forecast

What is FBIO's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$101.6M+76.07%
Avg 2 year Forecast
$141.7M+145.69%
Avg 3 year Forecast
$198.8M+244.69%
FBIO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

FBIO revenue growth forecast

How is FBIO forecast to perform vs Biotechnology companies and vs the US market?

Company
49.82%
Industry
64.17%
Market
10.07%
FBIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
FBIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

FBIO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
FBIO$1.77$21.00+1,086.44%Strong Buy
PRLD$0.96$4.50+368.75%Buy
PMVP$0.99$5.00+405.05%Buy
AVTX$4.98$34.20+586.75%Strong Buy
PEPG$1.57$10.33+558.15%Hold

Fortress Biotech Stock Forecast FAQ

Is Fortress Biotech Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: FBIO) stock is to Strong Buy FBIO stock.

Out of 2 analysts, 1 (50%) are recommending FBIO as a Strong Buy, 1 (50%) are recommending FBIO as a Buy, 0 (0%) are recommending FBIO as a Hold, 0 (0%) are recommending FBIO as a Sell, and 0 (0%) are recommending FBIO as a Strong Sell.

If you're new to stock investing, here's how to buy Fortress Biotech stock.

What is FBIO's earnings growth forecast for 2025-2027?

(NASDAQ: FBIO) Fortress Biotech's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.59%.

Fortress Biotech's earnings in 2025 is -$55,890,000.On average, 2 Wall Street analysts forecast FBIO's earnings for 2025 to be -$44,596,098, with the lowest FBIO earnings forecast at -$48,435,498, and the highest FBIO earnings forecast at -$40,756,699. On average, 2 Wall Street analysts forecast FBIO's earnings for 2026 to be -$29,681,509, with the lowest FBIO earnings forecast at -$31,601,209, and the highest FBIO earnings forecast at -$27,761,810.

In 2027, FBIO is forecast to generate -$13,585,566 in earnings, with the lowest earnings forecast at -$13,585,566 and the highest earnings forecast at -$13,585,566.

What is FBIO's revenue growth forecast for 2025-2027?

(NASDAQ: FBIO) Fortress Biotech's forecast annual revenue growth rate of 49.82% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.07%.

Fortress Biotech's revenue in 2025 is $57,675,000.On average, 2 Wall Street analysts forecast FBIO's revenue for 2025 to be $2,999,161,452, with the lowest FBIO revenue forecast at $2,135,296,632, and the highest FBIO revenue forecast at $3,863,026,272. On average, 2 Wall Street analysts forecast FBIO's revenue for 2026 to be $4,184,945,128, with the lowest FBIO revenue forecast at $3,730,123,992, and the highest FBIO revenue forecast at $4,639,766,264.

In 2027, FBIO is forecast to generate $5,871,327,392 in revenue, with the lowest revenue forecast at $5,871,327,392 and the highest revenue forecast at $5,871,327,392.

What is FBIO's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: FBIO) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 35.65%.

What is FBIO's Price Target?

According to 2 Wall Street analysts that have issued a 1 year FBIO price target, the average FBIO price target is $21.00, with the highest FBIO stock price forecast at $26.00 and the lowest FBIO stock price forecast at $16.00.

On average, Wall Street analysts predict that Fortress Biotech's share price could reach $21.00 by Mar 11, 2026. The average Fortress Biotech stock price prediction forecasts a potential upside of 1,086.44% from the current FBIO share price of $1.77.

What is FBIO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: FBIO) Fortress Biotech's current Earnings Per Share (EPS) is -$2.69. On average, analysts forecast that FBIO's EPS will be -$1.51 for 2025, with the lowest EPS forecast at -$1.64, and the highest EPS forecast at -$1.38. On average, analysts forecast that FBIO's EPS will be -$1.01 for 2026, with the lowest EPS forecast at -$1.07, and the highest EPS forecast at -$0.94. In 2027, FBIO's EPS is forecast to hit -$0.46 (min: -$0.46, max: -$0.46).

What is FBIO's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: FBIO) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.